AstraZeneca ’s Faslodex receives CHMP opinion for advanced breast cancer treatment

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for AstraZeneca ’s Faslodex (fulvestrant) to treat hormone receptor-positive (HR+) advanced breast cancer in combination wi…
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news